News

Once again, Roche breast cancer franchise shines, sending Q3 drug sales up 4%

Roche can thank its newly augmented breast cancer portfolio for powering third-quarter sales upward, far enough to surpass analyst estimates. And given the latest data on one of those drugs--Perjeta--more growth could be at hand.

Gilead, Allergan, Novo and Valeant chiefs make the list of world's top 10

Pharma CEOs are doing a pretty good job at the helm--at least where the Harvard Business Review is concerned.

Déjà vu for Celgene as NICE says 'no' to myeloma drug Imnovid

The U.K.'s cost-effectiveness watchdog has recently sounded a bit like a broken record when it comes to its cancer drug rejections. The latest to get a "no-go" from the gatekeeper? Celgene's Imnovid.

FDA grants a combo-med exclusivity wish. Why is that a problem?

What's two extra years of exclusivity worth? Enough to spark a legal fight. The FDA posted new guidance on its website Friday, awarding certain combo meds 5 years of exclusivity compared with the previous three. Drugmakers had lobbied for the change, but the timing--and the wording--are bound to be controversial.

Former Merck staffer charged in insider trading case

The latest pharma company to wind up in the middle of insider trading charges? Merck. A former employee at the drug giant has been charged after allegedly tipping off a former classmate about potential deals that scored him $683,000.

GSK starts unloading older meds by region, with $3B portfolio up for grabs

In its latest move to revive profits and slim down a sagging portfolio, GlaxoSmithKline is planning to put $3 billion worth of older drugs on the chopping block, shedding products by geographical region.

AbbVie-Shire deal in jeopardy, but not necessarily dead

Shire, which believed only a day ago that it would soon be bought out by AbbVie in a $54 billion deal prompted by tax advantages, is not going to just roll over and play dead now that its pursuer is getting cold feet. It insists the deal should go through.

Novartis' Russian growth plans get delayed

Novartis is reportedly caught between EU sanctions on Russia and the dictates of Russian President Vladimir Putin, who has told Western drugmakers that he expects them to build plants and transfer technology as the price of admission to the growing market.

FDA reviewers say Pfizer's Chantix should keep its black box

FDA staffers aren't as impressed with new safety data on Chantix as Pfizer wants them to be. In briefing documents filed in advance of Thursday's advisory committee meeting, reviewers say the stop-smoking remedy should keep its black-box warning about potential psychiatric side effects.

Could Gilead's $95K nod trigger creative payment ideas? Ask J&J and AbbVie

Alarmed payers are gearing up for another hepatitis C battle. Now that Gilead Sciences' new two-in-one infection fighter Harvoni is approved--and with a $94,500 price--it's worth looking at some strategies payers have used with other hep C drugs, including Sovaldi, the single-agent sibling to Harvoni.

J&J beats the Street for Q3, thanks to surging sales of standout drugs

Johnson & Johnson is riding the tailwinds of recent success, celebrating positive third quarter earnings buoyed by record-setting sales of its top products and the sell-off of its Ortho-Clinical Diagnostics business.

Sanofi wins kudos for airing bribery probe. Phase II? Take to social media

Last week, Sanofi told the feds it had hired an outside law firm to dive into an anonymous whistleblower's accusations of corruption in the Middle East. But the company's proactive approach may not be enough to block a blow to its reputation, experts say.

AstraZeneca photo campaign helps cancer patients swap stories on social media

AstraZeneca has launched a photo-sharing campaign on Twitter, Instagram and other social media sites to get women talking about their metastatic breast cancer (MBC).

The top 10 most expensive drugs of 2013

The price of Gilead Sciences' breakthrough drug Sovaldi has drawn all of the attention this year. By pricing it at $85,000 for a 12-week course, Gilead Sciences ($GILD) has been pilloried by...

Top U.S. execs flee Ranbaxy as Sun Pharma merger looms: paper

Ranbaxy Laboratories has been a steady source of bad news over the past several years. And now that India-based rival Sun Pharmacueticals is preparing to take over, the company's top U.S. leadership is throwing in the towel.

Pfizer breast cancer prospect grabs FDA's speedy review promise

Pfizer's pipeline could use a big approval, and it may have one coming in palbociclib.

UPDATED: Texas AG: AstraZeneca paid $465K in kickbacks, committed fraud in Seroquel marketing

Texas Attorney General Greg Abbott has sued AstraZeneca for fraud, saying that AstraZeneca sales reps misled doctors and state Medicaid officials about Seroquel's side effects, paid kickbacks to two influential state decision-makers, and promoted the powerful antipsychotic for off-label uses.

Payers hit back at Gilead for $94,500 price tag on brand-new hep C combo pill

So you thought Gilead's Sovaldi was expensive? Get ready for Harvoni, the company's all-oral hep C combo regimen that won FDA approval on Friday. Cost? $94,500 for a 12-week course of treatment.

India's NPPA fines Novartis $49M as price cap battles rage on

India's National Pharmaceutical Pricing Authority has fined Novartis the equivalent of $49 million for overpricing its popular pain drug Voveran, and Novartis has responded by challenging NPPA's authority to do so. The fine is just the latest move in an escalating battle between drugmakers and the NPPA.

Eisai adds to chemo side-effects franchise with FDA nod for Akynzeo

Months after launching a regulatory battle to extend exclusivity for two of its best-selling products, Eisai won FDA approval for its Akynzeo drug to treat common side effects in patients undergoing chemotherapy.